A 34-year-old woman who works as a librarian comes to the clinic because her fingers keep changing color. Cold air or emotional stress turns the fingers of both hands white, then blue. As they rewarm, they turn red and burn. Each episode lasts 10 to 15 minutes.

She has had occasional mild episodes since her early twenties. Over the past year, they have become longer and more frequent, and she now has several a week. They are interfering with her work in an air-conditioned building.

Past medical history: Migraine without aura. Propranolol extended-release 80 mg daily was started 14 months ago for prevention, and her migraine days fell from about eight a month to two. Cholecystectomy at age 28.

Medications: Propranolol ER 80 mg daily. Ibuprofen as needed for migraine attacks.

Social history: Never smoker. Drinks alcohol socially. No stimulants, decongestants, or other drugs. She and her partner hope to start a family in the next year or two.

Family history: Mother has hypothyroidism. Father has hypertension.

Vitals: Temperature 98.7°F, heart rate 62 bpm, blood pressure 118/74 mmHg, respiratory rate 16 bpm.

Physical exam: No sclerodactyly, puffy fingers, digital pitting, ulcers, or telangiectasias. Radial and ulnar pulses 2+ in both arms. Nailfold capillaries look normal on dermatoscopy. Heart, lungs, and the rest of the exam are normal.

See image below. (Representative photograph of the lesions involving the right hand, provided for illustration).

Labs: CBC normal. ESR normal. TSH normal. ANA negative by HEp-2 immunofluorescence.

You establish the diagnosis as primary Raynaud's phenomenon, worsening over the past year.

What is the most appropriate next best step in management?

A. Start nifedipine extended-release 30 mg daily now.

B. Taper propranolol, switch her migraine prevention to another agent, and start cold-protection measures.

C. Start sildenafil 20 mg three times daily now.

D. Prescribe topical nitroglycerin ointment for her fingers before cold exposure.

Choose your answer now before moving on.

Propranolol didn't cause her primary Raynaud's phenomenon, since she had it for a decade before the drug was started. But it got worse in the year after propranolol began, and that timing is the clue.

The evidence on this is real but modest, so it's worth stating precisely. A 2016 systematic review and network meta-analysis of 38 randomized trials covering more than 57,000 patients found peripheral vasoconstriction in 7% of patients on beta-blockers and 4.6% with control groups (P < 0.001). Propranolol and atenolol both carried a significantly higher risk than placebo. Pindolol, acebutolol and oxprenolol did not carry the same risk.

That is why B is the best first step. Switching costs little. Several other migraine preventives have good evidence, and none of them adds a new drug to treat a possible side effect of an old one. Propranolol should be tapered, not stopped abruptly, and the switch should be coordinated with whoever manages her migraines. Cold protection goes alongside it for every patient with Raynaud's: keep the whole body warm, not only the hands.

Reassess in six to eight weeks. If attacks are still frequent once propranolol is gone, it's time to add a drug.

A. Start nifedipine extended-release 30 mg daily

A dihydropyridine calcium channel blocker is plausible in this case, but cannot be termed the next best step, as starting it now without first tapering off propranolol is premature, and treats a likely side effect with a new drug and leaves the probable aggravator in place. In primary Raynaud's, the benefit is also modest, and headache and flushing are common side effects in a patient who already has migraine. It may be the right answer at step two, not step one.

C. Start sildenafil 20 mg three times daily

Sildenafil is generally reserved for secondary Raynaud’s that persists despite first-line treatment, with most supporting evidence coming from patients with systemic sclerosis. Here, the appropriate first step is to address propranolol as a possible aggravating factor and begin cold-protection measures. If symptoms remain troublesome, a dihydropyridine calcium channel blocker such as nifedipine is the usual first-line medication.

D. Prescribe topical nitroglycerin ointment for her fingers before cold exposure.

There is no conclusive evidence that topical nitrates reduce attack frequency in primary Raynaud's. Nitrates also commonly cause headache, which makes them a poor fit for a patient being treated for migraine.

When a stable chronic condition gets worse, look at what changed in the medication list before you add a drug. Here the timeline, a decade of mild symptoms and then a year of worsening that began after propranolol was started, points to the first step.

Raynaud's at the first visit: what to check and what to do first.

Primary pattern: onset in teens or twenties, both hands, no ulcers or pitting, normal pulses, normal nailfold capillaries, usually negative ANA.

Look harder for a secondary cause if: onset after about 40, one hand only, digital ulcers or pitting, puffy fingers, abnormal capillaries, or a positive ANA.

Review medications first: propranolol and atenolol (the beta-blockers with the clearest signal) and stimulants for ADHD.

Warmth: keep the whole body warm, not just the hands.

If still disabling: a dihydropyridine calcium channel blocker. Expect fewer attacks, not none.

Refer to rheumatology: if she isn't responding, or if any secondary feature appears.

Not every beta-blocker carries the same signal. In the 2016 systemic review and network meta-analysis, propranolol and atenolol increased peripheral vasoconstriction compared with placebo, but the beta-blockers with intrinsic sympathomimetic activity (pindolol, acebutolol, oxprenolol) did not show a statistically significant increase. If a patient with Raynaud's truly needs a beta-blocker, the choice of agent matters.

The answer said to switch her migraine prevention. Which drug to choose is harder than it looks, because she hopes to conceive in the next year or two.

Topiramate may be the reflex choice, and it may not be the best one for her. In a US cohort of more than 1.3 million pregnancies, first-trimester topiramate was associated with about three times the risk of oral clefts (4.1 vs 1.1 per 1,000 births), with the highest risk at doses above 100 mg. A Nordic registry study found its overall major-malformation risk was similar to valproate's.

Candesartan is the interesting option. A 2026 meta-analysis of four trials supports angiotensin receptor blockers for migraine prevention, mostly candesartan, with reduction in migraine days and headache days reaching statistical significance. A small 1999 pilot trial also suggested that losartan, another ARB, reduced Raynaud's attacks. But ARBs cause fetal kidney injury and are contraindicated in pregnancy. They're an option only with reliable contraception and a plan to stop before she tries to conceive.

Lisinopril also appears on migraine-prevention lists, but the 2021 Cochrane review found that ACE inhibitors may slightly increase Raynaud's attack frequency. They also carry the same pregnancy problem.

In practice: ask about her pregnancy plans before you choose. Amitriptyline is often used in this situation. Its safety in pregnancy should still be reviewed with her obstetric clinician before she conceives.

If she needs a drug after the switch, she should know what to expect. The 2016 Cochrane review in primary Raynaud's found that calcium channel blockers reduced attacks by about 1.7 per week compared with placebo, with little effect on how severe each attack was.

The broader 2017 Cochrane review, which included primary and secondary Raynaud's, looked more impressive at first: about six fewer attacks per week against a placebo baseline of 13.7. When one outlier trial was removed, the reduction fell to about three a week. Higher doses of dihydropyridines may work better, and the effect may be larger in primary than in secondary Raynaud's. The common side effects are headache, dizziness, flushing, palpitations and ankle swelling.

What to tell her: "This should mean fewer attacks, not no attacks." Patients who expect a cure can sometimes get disheartened if the attacks do not completely stop.

A 1998 meta-analysis followed 639 patients with primary Raynaud's. Of these, 12.6% later developed a secondary disorder, almost always a connective tissue disease, a mean of 10.4 years after their Raynaud's began. An abnormal nailfold capillary pattern was the best predictor at entry (positive predictive value 47%). ANA alone was weaker (30%).

The 2021 VEDOSS registry studied patients with Raynaud’s phenomenon to determine the clinical value of the very early diagnosis of systemic sclerosis (VEDOSS) criteria to identify those patients who were at risk for progression to systemic sclerosis within 5 years. What they found was that the absence of ANA is a strong protective factor that identifies patients with very low risk of developing systemic sclerosis with only 4 of 37 ANA-negative patients developing systemic sclerosis criteria within five years.

What would change the plan: New puffy fingers, digital ulcers or pitting, or a change in her capillaries. Any of these means repeating the ANA, checking systemic sclerosis-specific antibodies and referring to rheumatology. Without them, she needs a yearly review, not a workup.